Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Lamivudine helps keep HBV at bay during cancer chemotherapy
April 6th, 2004
Researchers in Hong Kong have discovered a way to help prevent the reactivation of the hepatitis B virus (HBV) in women who are being treated with chemotherapy for breast cancer. Winnie Yeo, an associate professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, told the 4th European Breast Cancer Conference in Hamburg: "In several developing countries, as many as 12% of breast cancer patients carry the hepatitis B virus. These patients are at risk of developing HBV reactivation during chemotherapy, which is a well-known complication resulting in varying degrees of liver damage that may lead to death." Chemotherapy...
Source: Cancer Weekly (2004-04-06)
|
